Mankind Pharma Reports Q2 Results; Provides Corporate Guarantee for BSV
Mankind Pharma Limited released its unaudited standalone financial results for the quarter ended June 30, 2026, reporting a profit of 558.49 crore. Concurrently, the company's consolidated earnings for the same period stood at 574.09 crore. The results reflect significant corporate activities, including the issuance of a substantial corporate guarantee in favor of its subsidiary, Bharat Serums and Vaccines Limited (BSV).The Board of Directors considered these financial outcomes along with operational updates concerning the acquisition of a generic business unit from BSV and the divestment of stake in Broadway Hospitality Services Private Limited. Mankind Pharma also granted 93,750 stock options to eligible employees during the quarter.
Standalone Financial Performance (Q2 FY26)
Mankind Pharma Limited recorded total income of 2,998.01 crore for the standalone entity, with a profit for the period of 558.49 crore. The company's earnings per equity share (EPS) stood at 13.53 in basic terms.A review by independent auditors found that nothing came to their attention to suggest that the results contained any material misstatement. Management’s note also highlighted ongoing uncertainty regarding income tax proceedings initiated against the company following a search conducted earlier under Section 132 of the Income Tax Act, 1961.
The standalone performance metrics for the quarter are summarized below:
| Particulars | Quarter ended 30.06.2026 (Unaudited) | Quarter ended 31.03.2026 (Audited) | Quarter ended 30.06.2025 (Unaudited) | Year ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 2,964.05 Cr | 2,581.82 Cr | 2,569.73 Cr | 10,421.18 Cr |
| Total income (I) | 2,998.01 Cr | 2,708.52 Cr | 2,634.94 Cr | 10,747.28 Cr |
| Total expenses (II) | 2,241.44 Cr | 1,897.69 Cr | 2,138.77 Cr | 8,326.04 Cr |
| Profit before tax (V) | 756.57 Cr | 788.01 Cr | 496.17 Cr | 2,315.00 Cr |
| Total tax expense (VI) | 198.08 Cr | 74.40 Cr | 80.90 Cr | 277.44 Cr |
| Profit for the period (VII) | 558.49 Cr | 713.61 Cr | 415.27 Cr | 2,037.56 Cr |
Consolidated Earnings and Strategic Moves
On a group level, Mankind Pharma reported consolidated revenue of 4,030.59 crore for the quarter. The company achieved a profit for the period of 574.09 crore.The consolidated results reflect several key strategic transactions:
- Acquisition: The Group acquired the Branded Generic Business relating to the Women's Health Portfolio from BSV for a consideration of 797 crore, effective November 1, 2025.
- Divestment: The company completed the sale of its 100% stake in Broadway Hospitality Services Private Limited for a cash consideration of 49 crore on July 27, 2026.
- Guarantee Issuance: Mankind Pharma approved the issuance of a corporate guarantee aggregating to ₹150 crores in favor of various banks to secure credit facilities availed by BSV.
The unaudited consolidated results for the quarter are detailed as follows:
| Particulars | Quarter ended 30.06.2026 (Unaudited) | Quarter ended 31.03.2026 (Audited) | Quarter ended 30.06.2025 (Unaudited) | Year ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 4,030.59 Cr | 3,442.93 Cr | 3,570.35 Cr | 14,277.64 Cr |
| Total income (I) | 4,075.59 Cr | 3,557.22 Cr | 3,650.23 Cr | 14,636.43 Cr |
| Total expenses (II) | 3,310.08 Cr | 2,877.88 Cr | 3,112.91 Cr | 12,185.69 Cr |
| Profit before tax (VII) | 769.45 Cr | 659.17 Cr | 540.49 Cr | 2,332.68 Cr |
| Total tax expense (VIII) | 195.36 Cr | 99.75 Cr | 95.87 Cr | 394.58 Cr |
| Profit for the period (IX) | 574.09 Cr | 559.42 Cr | 444.62 Cr | 1,938.10 Cr |
Financial Ratios and Debt Obligations
The company's financial position showed a Net worth of 16,967.03 crore for the quarter ended June 30, 2026. Management noted that the group engages only in one reportable segment: Pharmaceuticals.Key operational ratios include:
| Ratio | Quarter ended 30.06.2026 (Unaudited) | Quarter ended 31.03.2026 (Audited) | Quarter ended 30.06.2025 (Unaudited) | Year ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Debt equity ratio (times) | 0.25 | 0.34 | 0.48 | 0.34 |
| Net worth (~ Crores) | 16,967.03 | 16,396.94 | 14,763.59 | 16,396.94 |
| Current ratio (times) | 0.84 | 0.76 | 0.82 | 0.76 |
| Debt service coverage ratio (times) | 0.59 | 0.79 | 0.76 | 0.52 |
Other Financial Highlights
The unaudited standalone results included figures related to the acquired business unit from BSV:- Revenue from operations of the acquired entity: 29.61 crore.
- Profit after tax/Total comprehensive income of the acquired entity: 2.51 crore.
MANKIND Stock Price Movement
Mankind Pharma Limited shares slipped by 0.87% in post-market trading today, settling down after declining by ₹22.50 per share. The stock traded within a range of ₹2560.5 and ₹2605, accumulating a total traded volume of 226,509 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: